OrthoTrophix announced results of the first proof of principle study of TPX-100 in subjects with bilateral knee osteoarthritis, showing improvements at 6 and 12 months in key knee-related outcome measures.
TPX-100 is an injectable cartilage repair therapeutic agent. Initiated in 2014, the Phase II clinical trial evaluated intra-articular injections of TPX-100 in 115 cases of mild to moderate patello-femoral osteoarthritis involving both knees.
Safety and tolerability of TPX-100 were excellent, and the majority of standardized, patient-reported measures of knee daily function, quality of life and sports/recreation function demonstrated statistically significant and clinically meaningful improvements in the TPX-100-treated knees vs. those receiving placebo.
OrthoTrophix announced results of the first proof of principle study of TPX-100 in subjects with bilateral knee osteoarthritis, showing improvements at 6 and 12 months in key knee-related outcome measures.
TPX-100 is an injectable cartilage repair therapeutic agent. Initiated in 2014, the Phase II clinical trial evaluated intra-articular...
OrthoTrophix announced results of the first proof of principle study of TPX-100 in subjects with bilateral knee osteoarthritis, showing improvements at 6 and 12 months in key knee-related outcome measures.
TPX-100 is an injectable cartilage repair therapeutic agent. Initiated in 2014, the Phase II clinical trial evaluated intra-articular injections of TPX-100 in 115 cases of mild to moderate patello-femoral osteoarthritis involving both knees.
Safety and tolerability of TPX-100 were excellent, and the majority of standardized, patient-reported measures of knee daily function, quality of life and sports/recreation function demonstrated statistically significant and clinically meaningful improvements in the TPX-100-treated knees vs. those receiving placebo.
Copy to clipboard 
